Definiens
Definiens AG, founded in 1994 in Munich, Germany, develops software for biomedical image analysis in digital pathology, serving biopharma, clinical research, and diagnostics customers seeking automated quantitative image interpretation.
- Company typePrivate
- Founded1994
- HeadquartersMunich, Germany
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
Definiens firmographics
Firmographics- Name
- Definiens
- Legal name
- Definians AG
- Website
- https://definiens.com
- Company type
- Private
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Definiens AG, founded in 1994 in Munich, Germany, develops software for biomedical image analysis in digital pathology, serving biopharma, clinical research, and diagnostics customers seeking automated quantitative image interpretation.
- Ownership category
- akta.pro rank
Definiens industry classification
Industry- Product category
- Digital Pathology Software
- NAICS
- Software Publishers (513210), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Prepackaged Software (7372), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Medical Imaging AI (HDAAAEAH)
- akta.pro secondary industries
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where Definiens is headquartered
LocationHeadquarters
- HQ city
- Munich
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Definiens business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Definiens product offering
Product offeringCore offering
Definiens develops and sells software solutions for quantitative analysis of biomedical images, with a focus on digital pathology and tissue-based diagnostics. Its offerings support research institutions, pharmaceutical companies, and clinical laboratories in automating the interpretation of complex microscopy and histology images for biomarker discovery and diagnostic applications.
Differentiator
Problem solved
Functional benefit
Products and services
- Biomedical Image Analysis Software Software platform for automated quantitative analysis and interpretation of biomedical and tissue images, serving pharmaceutical companies, biotech firms, and clinical research institutions for biomarker discovery and digital pathology applications.
- Biomedical Data Mining Solutions Data mining tools that extract diagnostic and research-relevant insights from large volumes of biomedical image data, used by healthcare and life sciences institutions to support research and diagnostic decisions.
- Predictive Tests Predictive diagnostic tests enabled by Definiens' biomedical image analysis technology, developed for clinical and pharmaceutical customers seeking image-based predictive biomarkers.
Companies that use Definiens
Customer profileSegments1 record
Ideal customer profiles2 records
Definiens technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Definiens partnerships and signals
Strategic signalScale indicators2 records
Definiens competitors and assessment
Company assessmentDirect peers
- PathAI: PathAI develops AI-powered pathology diagnostics and biomarker discovery tools, directly overlapping with Definiens' tissue image analysis and digital pathology focus. Both target biopharma and clinical diagnostics customers with deep-learning-based image interpretation.
- Paige: Paige builds AI applications for pathology, including FDA-cleared diagnostic software for prostate and breast cancer. Its focus on computational pathology directly competes with Definiens in tissue-based image analytics for oncology.
- Proscia: Proscia offers a digital pathology platform with AI-enabled image analysis for life sciences and diagnostics. It overlaps with Definiens in serving pharma R&D and clinical pathology workflows with quantitative image insights.
- Aiforia: Aiforia provides AI-based image analysis software for digital pathology, serving preclinical and clinical researchers in pharma and diagnostics. It competes head-to-head with Definiens in tissue phenotyping and biomarker quantification.
- Visiopharm: Visiopharm delivers image analysis and AI solutions for quantitative digital pathology used in research and clinical diagnostics. Its phenotyping and tissue analysis capabilities overlap directly with Definiens' core offering.
- Indica Labs: Indica Labs develops AI-driven image analysis software for pathology, including HALO platforms used in pharma R&D. Its quantitative tissue analysis capabilities make it a direct functional competitor to Definiens.
Emerging players
- Owkin: Owkin applies AI to pathology and multimodal biomedical data for drug discovery and diagnostics. While broader than Definiens (spanning imaging, clinical, and omics data), it overlaps meaningfully in AI-driven pathology for pharma/biotech.
Broad incumbents
- Roche Digital Pathology: Roche (via Roche Diagnostics and Ventana) offers a comprehensive digital pathology platform including whole-slide imaging and AI image analysis. It is a broad incumbent competing with Definiens across pharma and clinical pathology.
- Philips Digital Pathology: Philips provides enterprise digital pathology solutions (IntelliSite) with image management and AI-enabled analysis. As a broad healthcare incumbent, it competes in the same integrated workflow layer as Definiens for hospital and lab deployments.
- Hamamatsu Photonics: Hamamatsu supplies whole-slide scanners and digital pathology infrastructure used alongside image analysis software. It is an upstream/imaging incumbent adjacent to Definiens in the digital pathology stack.
Market position
Customer concentration
Definiens social profiles
Digital presenceDefiniens financial estimates
Financial estimateRevenue estimate
Valuation estimate
Definiens leadership team
Management profileNumber of profiles
Profiles3 records
Definiens funding detail
Funding detailFunding overview
Funding rounds3 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Definiens M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Definiens
What does Definiens do?
Definiens develops and sells software solutions for quantitative analysis of biomedical images, with a focus on digital pathology and tissue-based diagnostics. Its offerings support research institutions, pharmaceutical companies, and clinical laboratories in automating the interpretation of complex microscopy and histology images for biomarker discovery and diagnostic applications.
Is Definiens a public or private company?
Definiens is a private company. It is classified as venture growth investor backed and is currently operating.
When was Definiens founded?
Definiens was founded in 1994. It employs 51 to 100 people.
Where is Definiens based?
Definiens is headquartered in Munich, Germany, in the Europe region.
Who are Definiens's main competitors?
Direct peers on record are PathAI, Paige, Proscia, Aiforia, Visiopharm and Indica Labs. Owkin is listed as an emerging player. Broad incumbents are Roche Digital Pathology, Philips Digital Pathology and Hamamatsu Photonics.
Does Definiens have an API?
No public API is recorded for Definiens.
What industry is Definiens in?
Definiens's product category is Digital Pathology Software. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 513210 and its SIC code is 7372.